$ENZ to $2.94 LONG - Monthly setup is strong3/16/23 - Enzo Biochem (ENZ) stock is rising higher on an asset sale agreement.
It’s selling its Clinical Laboratory division to Labcorp (LH).
3/20/23 - Monthly GD on MC.
8/23/23 - $3 per share.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.51 USD
−26.08 M USD
31.91 M USD
36.47 M
About Enzo Biochem, Inc.
Sector
Industry
CEO
Kara Cannon
Website
Headquarters
New York
Founded
1976
FIGI
BBG000BHY9Q4
Enzo Biochem, Inc. is an integrated diagnostics, clinical lab, and life sciences company, which engages in the manufacture, development and market of products and tools for clinical research, translational research, drug development and bioscience research. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in August 1976 and is headquartered in New York, NY.
$ENZ is gonna fall todayPupm&Dump trading strategy idea.
$ENZ is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $3,48;
stop-loss — $3,67;
take-profit — $3,12.
Do not view thi
Enzo Biochem spiked on 43x average volumeEnzo Biochem spiked on 43x average volume. This is highly volatile price action. Enzo Biochem (ENZ) reported Quarter January 2021 earnings of $0.09 per share on revenue of $31.5 million. Revenue grew 62.3% on a year-over-year basis. Enzo Biochem Inc is engaged in research, development, manufacturing
ENZ Spike Higher After FDA EUA For Its AMPIPROBEShares Of Enzo Life Sciences Spike Higher After Co. Gets FDA Emergency Use Authorization For Its AMPIPROBE Coronavirus Test System
Enzo Biochem (NYSE:ENZ) soared 21% yesterday as its Ampiprobe SARS-CoV-2 Test System was granted Emergency Use Authorization by the FDA in a letter.
The letter stated,
ENZ just getting noticed -not your typical stupid Corona coThis is the real deal from a fundamental perspective 1.00 in cash no debt, activist bought 12% of co. and put 2 people on the board before Corona ever became a thing and they bought their 12% position at $3.07 , 400 patents 80mm in revenue and insiders have bought between 2.20-3.65 - oh and yes
ENZO BIOCHEM INC - NYSE: $ENZ FlaggingLast week, ENZO BIOCHEM INC - NYSE:ENZ broke to higher ground and in the process, recaptured its 200 DMA out of a rounding bottom and now finds itself digesting/consolidating the move within a Flag pattern on lower volume as is evidenced in the Daily chart above.
In addition, ENZ is now trading
Double bottom, next stop $5. Fib lines show next price targets.Nice play here. THere might be a slight pullback mid week, and wait to confirm candle closes above previous highs before entering. Ichi on the daily is big time bullish for the first time in a LONG TIME.
ENZ on watch.Double bottom on the weekly, could very easily hit 4.90 this week. Confirmed buy the breakout past 4.20. Price Target #2 would be 5.43.
See all ideas
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of ENZ is 1.15 USD — it has increased by 1.77% in the past 24 hours. Watch Enzo Biochem, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Enzo Biochem, Inc. stocks are traded under the ticker ENZ.
ENZ stock has risen by 0.88% compared to the previous week, the month change is a 1.77% rise, over the last year Enzo Biochem, Inc. has showed a −10.23% decrease.
ENZ stock is 2.68% volatile and has beta coefficient of 0.84. Track Enzo Biochem, Inc. stock price on the chart and check out the list of the most volatile stocks — is Enzo Biochem, Inc. there?
Today Enzo Biochem, Inc. has the market capitalization of 60.08 M, it has increased by 0.65% over the last week.
Yes, you can track Enzo Biochem, Inc. financials in yearly and quarterly reports right on TradingView.
Enzo Biochem, Inc. is going to release the next earnings report on Dec 11, 2024. Keep track of upcoming events with our Earnings Calendar.
ENZ net income for the last quarter is −13.38 M USD, while the quarter before that showed −3.02 M USD of net income which accounts for −343.08% change. Track more Enzo Biochem, Inc. financial stats to get the full picture.
As of Nov 10, 2024, the company has 136.00 employees. See our rating of the largest employees — is Enzo Biochem, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Enzo Biochem, Inc. EBITDA is −8.46 M USD, and current EBITDA margin is −26.52%. See more stats in Enzo Biochem, Inc. financial statements.
Like other stocks, ENZ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Enzo Biochem, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Enzo Biochem, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Enzo Biochem, Inc. stock shows the sell signal. See more of Enzo Biochem, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.